Loading
Leads the next wave of endocrine therapy: oral SERDs like imlunestrant and the PI3K inhibitor inavolisib.
Komal Jhaveri led EMBER-3, which showed the oral SERD imlunestrant plus abemaciclib improves progression-free survival in ER-positive advanced breast cancer after aromatase inhibitors, and was a lead investigator on INAVO120 (inavolisib for PIK3CA-mutant disease). She heads endocrine therapy research at MSKCC and runs early-phase trials of degraders and PI3K pathway agents.
Shares Abemaciclib, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Palbociclib, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Abemaciclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Inavolisib, PIK3CA / PI3K-alpha, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.